Gene-editing therapies, particularly for neurological conditions, are not yet mature enough for widespread human trials, according to Stanford University expert Karoly Nikolich. He estimates that it could take up to five years before such treatments are ready for human testing. Nikolich cited two recent cases where patients died following experimental gene-editing treatments, highlighting the need for further research to understand the full-body effects of gene modification. AI
IMPACT AI approaches may accelerate the development timeline for gene-editing therapies, but current safety concerns remain.
RANK_REASON Expert opinion on the readiness of gene-editing therapies for human trials, citing specific cases.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
